Michael Wang, MD

Articles

Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL

January 21st 2020

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Wang on Precision Medicine in MCL

January 17th 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Dr. Wang on the Benefit of BTK Inhibitors in MCL

January 6th 2020

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCL

November 2nd 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Dr. Wang on Toxicity Profiles of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

October 9th 2019

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

Dr. Wang on Triplet Vorinostat Regimen in Newly Diagnosed MCL

September 25th 2019

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Dr. Wang on CAR T-Cell Therapy Resistance in MCL

September 20th 2019

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCL

September 6th 2019

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Dr. Wang on the Pace of Progress in MCL

June 25th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

Dr. Wang on Challenges Treating Patients With Relapsed/Refractory MCL

June 13th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Wang Discusses the Future of Treatment in MCL

May 24th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

Dr. Wang Discusses Promise of Venetoclax in MCL

March 2nd 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL

February 14th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Dr. Wang Discusses Next Steps With Acalabrutinib in MCL

January 12th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Dr. Wang Discusses Single-Agent Acalabrutinib in MCL

January 8th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of single-agent acalabrutinib in the treatment of mantle cell lymphoma.

Dr. Wang Discusses New Agents in the Field of MCL

November 7th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses new agents in the field of mantle cell lymphoma (MCL).

Dr. Wang Discusses the Treatment of Relapsed/Refractory MCL

October 16th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Wang on Managing AEs Related to BTK Inhibitors

September 27th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Wang Discusses the ZUMA-2 Trial in Mantle Cell Lymphoma

June 12th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. Wang Discusses Acalabrutinib in MCL

December 22nd 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.